India, June 13 -- Biotech startup Zumutor Biologics has raised $7.3 Mn (about Rs.70 Cr) in its Series B funding round from existing investors Accel and Bharat Innovation Fund, alongside new investors Premji Invest, and angel investors like Ashish Kacholia and Raj Dandu.

The startup said it plans to use the funds to complete its ongoing US FDA Phase 1 clinical study of its drug ZM008, both as a monotherapy and in combination regimens. It will also use the capital to initiate Phase 1B expansion cohorts and global Phase 2 studies, including in India.

Founded in 2013 by Kavitha Iyer Rodrigues, Zumutor develops immunotherapy drugs that activate the body's natural immune cells, particularly natural killer (NK) cells, to attack tumours and imp...